We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Microneedles have been around for the past two decades; however, recent advances in technology have enabled their manufacturing in a variety of different forms and at lower cost than previously possible. The technologies, ranging from hollow, solid, coated to dissolving, have captured the interest of many vaccine and drug manufacturers as an alternate form of delivery primarily due to the potential advantages associated with transdermal and intradermal delivery.
West recently attended the 5th International Conference on Microneedles at the University of British Columbia in Vancouver, Canada May 29 – June 1. The event included attendees from across the globe and provided a multi-day microneedle overview on various topics such as Global Vaccination Challenges, Diagnostics & Wearables, Needs & Opportunities, Commercialization and Regulatory Adoption, to name a few. Of particular interest, Dr. Yotam Levin, CEO of NanoPass Technologies Ltd., a West strategic business partner, presented and chaired a session titled “Vaccines and Immunotherapy.”
As a variety of speakers representing organizations such as WHO, CDC, Gates Foundation, and PATH spoke about challenges to immunization, common themes emerged, such as:
West offers several devices that meet these challenges. The West Intradermal Adapter is a snap-on guiding device designed to help reduce the need for a skilled administrator when performing an intradermal injection with a syringe. West’s Administration System devices provide needle-free solutions to reconstitute and transfer lyophilized and powdered drugs. Through our business partner NanoPass Technologies Ltd., the MicronJet600™ (microneedle system) addresses concerns around both injection pain and needle phobia, as well as reducing the skill level needed for a successful and reliable intradermal delivery.
The conference concluded with a panel discussion moderated by an FDA representative to review the needs and opportunities around the use of microneedles. West’s Dr. Alex Lyness, (Mgr. Research and Technology, Innovations R&D) was one of four industry panelists, including representatives from GSK, Merck and L’Oreal, invited by the conference to participate in this discussion.
For more information on West’s solutions and services in support of intradermal drug delivery and microneedle technologies, please visit our intradermal delivery page on our website.
MicronJet600™ is a trademark of NanoPass Technologies Ltd.
Vaccines have helped reduce the instance of infectious diseases around the globe, nearly eradicating past plagues, such as smallpox and polio. A very effective method of delivery is intradermal (ID) injection – now made easier with two novel products on the market.
In a <a href="/zh-cn/blog/2017/july/new-technology-for-delivery-of-vaccines">previous blog post</a>, we discussed various devices and solutions used to overcome the challenges associated with Intradermal (ID) injections. These challenges are mainly associated with the Mantoux Technique, a manual ID injection using a needle and syringe. Lacking the skill needed for this technique creates a risk of injecting the product too deep or not sufficiently deep and rendering the dose either less or potentially ineffective. Previous posts also touched on some of the potential benefits associated with ID delivery when compared to the more familiar Subcutaneous or Intramuscular type injections. Two of the benefits we look at closer in this post are dose sparing and improved immune response. Additionally, we will see how these two benefits can be related. <br />
Designed to help improve consistency and reliability of intradermal inject.
As the adoption and acceptance of self-administered therapies grows, patients are spending less time with physicians and are playing a greater role in the delivery and management of their treatments. With the growing demand for extended-release and high-concentration formulations, more drug delivery systems choices are now available to differentiate drug products in a crowded market. Patient preferences can drive the selection of self-injection systems for a drug therapy. Selecting a system that patients prefer can, simplify use and increase compliance with the dosage regimen.
Cancer affects all of us, whether we are a patient, a family member, a friend, or a colleague of someone fighting cancer. Working together, we can increase our understanding of this disease and support the groundbreaking research that is ongoing in the fight against cancer.
English
Chinese
